Shares of Jubilant Pharmova Limited touched Rs 985.95 on 25 June after its arm won a tentative USFDA nod for an antacid drug.

Most people know GERD as persistent acid reflux. The drug itself is Pantoprazole Sodium Delayed Release Oral Suspension, 40 mg per packet.

It is a liquid formulation meant for patients who need an alternative to the standard tablet version of the medicine. The approval was granted to Jubilant Generics Limited, a subsidiary of Jubilant Pharma, which is wholly owned by Jubilant Pharmova.

The Noida-based pharma firm disclosed the development through a stock exchange filing on 26 June, noting the USFDA communication arrived on 25 June. This is a tentative approval. Not final yet.

The hold-up is a patent. The reference drug this product is benchmarked against in the US is still under patent protection until December 2026. Full commercial approval is expected once that patent lapses.

The facility behind this approval is the company’s solid dosage manufacturing plant in Roorkee, Uttarakhand. The USFDA had already conducted a pre-approval inspection there in August 2025, and this clearance flows directly from that visit.

The Q4 FY26 numbers tell a split story. Net sales grew 18.60% year-on-year to Rs 2,272.20 crore, which is solid. But net profit fell 22.27% to Rs 119.40 crore, and EBITDA margin slipped from 17.9% to 14.8% as operating costs rose faster than revenue.

Ready to invest like a pro? Tradz by EquityPandit app equips you with 100+ Free tools and knowledge you need to succeed. Download the Tradz by EquityPandit app and gain access to daily stock lists and insightful market analysis and much more!